Corporate & Investor Presentation

Q3 FY22 financial results $ in millions, except per share amounts Revenue Non-GAAP gross margin* Non-GAAP operating income* Non-GAAP EPS* 3Q22 $864.5 +12%, +14% CC 58.1% (150) bps $253.0 +5% $1.32 +2% * Refer to Non-GAAP reconciliations in the Appendix. 28 © 2022 ResMed | Corporate & Investor Presentation - updated 28APR22 Diversified revenue by business & by geography OOH SaaS 12% Masks & Other 38% Revenue by business 3Q22 Devices 50% OOH SaaS 12% Europe, Asia, and Other 33% Revenue by region 3Q22 U.S., Canada, and Latin America 55% ResMed

View entire presentation